- Home
- ERAS vs GUG Comparison
ERAS vs GUG Comparison
Compare ERAS & GUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERAS
- GUG
- Stock Information
- Founded
- ERAS 2018
- GUG 2021
- Country
- ERAS United States
- GUG United States
- Employees
- ERAS N/A
- GUG N/A
- Industry
- ERAS Biotechnology: Pharmaceutical Preparations
- GUG Trusts Except Educational Religious and Charitable
- Sector
- ERAS Health Care
- GUG Finance
- Exchange
- ERAS Nasdaq
- GUG Nasdaq
- Market Cap
- ERAS 432.6M
- GUG 499.3M
- IPO Year
- ERAS 2021
- GUG N/A
- Fundamental
- Price
- ERAS $1.16
- GUG $14.37
- Analyst Decision
- ERAS Strong Buy
- GUG
- Analyst Count
- ERAS 6
- GUG 0
- Target Price
- ERAS $4.83
- GUG N/A
- AVG Volume (30 Days)
- ERAS 2.3M
- GUG 108.9K
- Earning Date
- ERAS 05-07-2025
- GUG 01-01-0001
- Dividend Yield
- ERAS N/A
- GUG 9.67%
- EPS Growth
- ERAS N/A
- GUG N/A
- EPS
- ERAS N/A
- GUG N/A
- Revenue
- ERAS N/A
- GUG N/A
- Revenue This Year
- ERAS N/A
- GUG N/A
- Revenue Next Year
- ERAS N/A
- GUG N/A
- P/E Ratio
- ERAS N/A
- GUG N/A
- Revenue Growth
- ERAS N/A
- GUG N/A
- 52 Week Low
- ERAS $1.01
- GUG $12.71
- 52 Week High
- ERAS $3.45
- GUG $15.06
- Technical
- Relative Strength Index (RSI)
- ERAS 41.47
- GUG 40.51
- Support Level
- ERAS $1.01
- GUG $14.09
- Resistance Level
- ERAS $1.29
- GUG $14.68
- Average True Range (ATR)
- ERAS 0.17
- GUG 0.40
- MACD
- ERAS 0.00
- GUG -0.01
- Stochastic Oscillator
- ERAS 31.25
- GUG 32.19
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
About GUG Guggenheim Active Allocation Fund of Beneficial Interest
Guggenheim Active Allocation Fund is a diversified closed-end management investment company. The fund's investment objective is to maximize total return through a combination of current income and capital appreciation. The company invests in both fixed-income and other debt instruments selected from a variety of sectors and credit qualities, and may also invest in equities. It uses tactical asset allocation models to determine the optimal allocation of its assets between fixed-income and equity securities. A majority of its investments are made in corporate bonds and the rest in senior floating rate interests, asset-backed securities, preferred stocks, and other securities.